AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Theravance Biopharma Inc
Video analysis: TBPH
All videosNo video analysis for this stock yet. Request one from our team.
News: TBPH
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $16.95 and traded as high as $17.10. Theravance Biopharma shares last traded at $17.06, with a volume of 251,659 shares changing hands. Analyst Upgrades and Downgrades
Empowered Funds LLC Purchases Shares of 55,463 Theravance Biopharma, Inc. $TBPH
Empowered Funds LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ: TBPH) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 55,463 shares of the biopharmaceutical company's stock, valued at approximately $900,000. Empowered Funds LLC owned 0.11% of Theravance
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share.Hal
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Theravance and its board of directors violat.
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restructuring and transaction costs) Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment 2 Quarter-end cash balance of $388 million and no debt DUBLIN, Aug. 10, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026. "During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.
Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP boosted its holdings in Theravance Biopharma, Inc. (NASDAQ: TBPH) by 14.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 983,615 shares of the biopharmaceutical company's stock after purchasing an additional 124,658 shares during
